Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-Fluorouracil, doxorubicin, and mitomycin-C

Logothetis, Christopher J.; Samuels, Melvin L.; Ogden, Sheryl

doi:10.1016/0090-4295(85)90121-9

Cited by 77 publications

(50 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Case reports of signet-ring cell carcinoma originating from different primary sites but also adenocarcinomas of the bladder indicate similar experiences in as much that responses, if encountered, appear to follow 5-FU-based regimens. [14][15][16] The kinetics of plasma CA19-9/CEA levels in our patient accurately matched the clinical and imaging behavior of the tumour. Elevated serum carbohydrate antigen 19-9 and CEA has been found to be elevated in signet-ring cell carcinoma in the past.…”

Section: Discussionmentioning

confidence: 90%

Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Michels

Barbour

Cavers

et al. 2013

CUAJ

View full text Add to dashboard Cite

Signet-ring cell cancers deriving from the bladder are rare entities and usually present with advanced incurable disease and associated poor outlook. No standard effective chemotherapeutic option has been described largely due to the rarity of this malignancy. We report a case of a patient with metastatic bladder cancer, signet-ring cell variant. The patient progressed rapidly on standard first-line bladder cancer chemotherapy with gemcitabine and carboplatin. He responded well to second-line capecitabine with a clinically meaningful progression-free survival.

show abstract

Section: Discussionmentioning

confidence: 90%

Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Michels

Barbour

Cavers

et al. 2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Logothetis et al reported two CDDP-resistant cases which responded to 5-FU-based chemotherapy and suggested that a 5-FU-based regimen is effective for adenocarcinoma of the bladder. 9 Nevin et al and Hatch et al reported four cases in total which responded to intra-arterial 5-FU infusion and irradiation. 10,11 In addition, 5-FU in combination with LV and/or CDDP has been clinically used in gastrointestinal adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

Intra‐arterial infusion of 5‐fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder*

Awakura¹,

Yamamoto²,

Fukuzawa³

et al. 1999

Int J of Urology

View full text Add to dashboard Cite

Background: Primary invasive adenocarcinoma of the urinary bladder was diagnosed in a 59-yearold man with a 6-month history of macrohematuria. Methods: He was treated with intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin and underwent radical cystectomy and construction of ileal conduit. Results:The pathologic examination of the specimen revealed no viable malignant cells. Conclusion: 5-Fluorouracil combined with leucovorin and/or cisplatin has been used in the treatment of gastrointestinal adenocarcinoma and may be useful in primary adenocarcinoma of the bladder.

show abstract

“…There is no firm evidence that palliative chemotherapy confers survival benefit in recurrent, metastatic urachal cancer and there are few case reports on the use of systemic chemotherapy [7,18,28,29]. Logothetis et al [30 ]reported that 2 of 3 patients who received 5-FU-based chemotherapy (5-FU, doxorubicin and mitomycin-C) showed a partial response. In 2003, the M.D.…”

Section: Discussionmentioning

confidence: 99%

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Jung¹,

Sun²,

Park³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

Background: Urachal cancer is a rare malignancy that accounts for <1% of bladder cancers. There is currently no consensus on the diagnosis and management of urachal cancer and there are very few reports on palliative chemotherapy for unresectable disease. We delineate the clinical features and treatment outcome of urachal cancer, in particular the relevance of palliative chemotherapy in recurrent, metastatic disease. Methods: The clinicopathologic variables and treatment outcome of patients who were treated for urachal cancer were retrospectively reviewed. Results: Among 28 eligible patients, 25 had localized disease and 3 had metastatic disease at initial diagnosis. All patients with localized disease underwent curative resection and there was disease recurrence in 10. Out of 13 patients with metastatic disease either at initial diagnosis or during follow-up, the lung was the most common metastatic site (n = 5), followed by the liver, bone and peritoneum. Ten patients received palliative chemotherapy. A total of 24 chemotherapeutic regimens were administered; regimens with a base of fluoropyrimidine (5-FU), taxane and gemcitabine were the most common. The overall response rate of all chemotherapeutic regimens was 16.7%. The 5-FU-based regimens showed a good response, with 2 of 4 patients who received these showing a partial response. One tumor with a partial small-cell component showed a partial response to both an etoposide-based regimen and a taxane-based regimen. Conclusions: In urachal cancer, curative surgery is still the recommended treatment with respect to overall survival. A 5-FU-based chemotherapy regimen could be considered for metastatic recurrent disease. © 2014 S. Karger AG, Basel

show abstract

Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-Fluorouracil, doxorubicin, and mitomycin-C

Cited by 77 publications

References 2 publications

Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Metastatic signet-ring cell cancer of the bladder responding to chemotherapy with capecitabine: case report and review of literature

Intra‐arterial infusion of 5‐fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder*

Treatment Outcome and Relevance of Palliative Chemotherapy in Urachal Cancer

Contact Info

Product

Resources

About